The European Medicines Agency (EMA) have classified LIfT's enhanced allogeneic granulocyte therapy as a somatic cell therapy MP, a type of Advanced Therapeutic Medicinal Product (ATMP).
LIfT BioSciences CEO, Alex Blyth, commented that "ATMP status (rather than being a medical procedure) in an orphan disease like Pancreatic Cancer, gives LIfT BioSciences significant advantages in getting to market faster with the Early Access Scheme off a single step trial and a Market Exclusivity license. Subject of course to the planned small clinical trial showing the same kind of great results we have seen in the lab. But this is certainly an important step forward".
Copyright © 2023 Stevenage Bioscience Catalyst